AQST Aquestive Therapeutics, Inc.
$3.99▲ +0.00%
Unknown
Other
Last sync: just now
Syncing
Key Metrics & Fundamentals
Market Cap
$500.55M
P/E Ratio
–
Div Yield
–%
52W Range
2.93 - 7.55
% vs 50 MA
-3.80%
% vs 200 MA
-18.29%
RSI-14
45.8
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.43
Free Cash Flow
-$14.86M
Gross Rev
$14.45M
Gross Profit
$10.98M
EBITDA
-$4.01M
COGS
$3.47M
Operating Exp
$15.18M
Operating Income
-$4.20M
EBIT
-$4.20M
Pretax Income
-$8.06M
Net Income
-$8.06M
EPS (Diluted)
-0.07
Price & Volume History
Volume (M)
Financial Overview - Income Statement
Quarterly
Mar 2026 (Quarterly)
Social Sentiment
Avg +0.10 · 4 posts
FDA just published the full CRL for AQST / Anaphylm - Showing critical issues that AQST tried to downplay
r/stocks · Mar 5, 2026
The post highlights 'critical issues' AQST tried to downplay, indicating a negative sentiment regarding the company's prospects.
negative
-0.80
TradeDiscussionStrongest stocks 45 minutes after open
r/StockMarket · Feb 2, 2026
AQST is identified as a top performer, generating positive sentiment.
positive
+0.50
DDNewsDiscussion🚨 $AQST DD 🚨 Battle of the Drug Dealers: $AQST vs $SPRY vs Epipen (FDA Jan 31 Catalyst)
r/wallstreetbets · Sep 24, 2025
The post focuses on AQST as part of a comparative analysis and potential catalyst.
positive
+0.60
DDDiscussionAQST - Helping your allergen ridden customers from getting you sick.
r/wallstreetbets · Sep 7, 2025
The post is a highly negative and hyperbolic scenario, fueled by a sarcastic and alarming situation. It's a creative, but unsettling, hypothetical.
negative
+0.10
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not Financial Advice.
All data, scores, charts, and analysis on this site are provided for informational and educational purposes only
and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
Always consult a qualified financial advisor before making any investment decisions.
See our Legal Notice for full details.